

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Dollinger, H. et al ) Art Unit:  
Serial No. : To Be Accorded ) Examiner:  
Confirmation No. : To Be Accorded  
Filed : October 16, 2001  
For : Neurokinin Antagonists  
Docket No. : 1/1154



Commissioner for Patents  
Washington, D.C. 20231

October 16, 2001

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56 and a copy of the document cited on the PTO-1449 form. **The document cited (WO 97/32865) is discussed at page 1 of the specification.**

**Applicants also bring to the attention of the Examiner the following nonprovisional patent application filed concurrently with the present application: Attorney Docket No 1/1155; Dollinger et al.; filed 10/16/01; (copy attached).**

☒ 1.97(b). This Statement is being filed within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or before the mailing of a first Office Action on the merits, whichever event occurs last.

☒ The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Philip I. Datlow".

Philip I. Datlow  
Reg. No. 41,482

Patent Department  
Boehringer Ingelheim Corp.  
900 Ridgebury Road  
P.O. Box 368  
Ridgefield, CT. 06877  
Tel.: (203) 798-4542



+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				<b>Application Number</b>	To Be Accorded
				<b>Filing Date</b>	October 16, 2001
				<b>First Named Inventor</b>	Horst DOLLINGER
				<b>Group Art Unit</b>	
				<b>Examiner Name</b>	
<b>Sheet</b>	<b>1</b>	<b>of</b>	<b>1</b>	<b>Attorney Docket Number</b>	1/1154

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+